(Stroke. 1996;27:76-81.)
© 1996 American Heart Association, Inc.
Articles |
Lubeluzole in Acute Ischemic Stroke
A Double-blind, Placebo-Controlled Phase II Trial
From Neurologische Universitätsklinik, Essen, Germany (H.C.D.); Neurologische Universitätsklinik, Heidelberg, Germany (W.H.); Neurologische Universitätsklinik, Mannheim, Germany (M.H.); Neurologische Universitetssjukhuset, Linköping, Sweden (J.R.); Janssen Research Foundation, Beerse, Belgium (L.H.); A.Z. Vrije Universiteit Brussel, Brussels, Belgium (J. De K.); for the Lubeluzole International Study Group (see Appendix for participants).
Correspondence to H.C. Diener, MD, Neurologische Universitätsklinik Essen, Hufelandstr 55, 45122 Essen 1, Germany.
Background and Purpose We aimed to assess the safety and efficacy of lubeluzole in patients with a clinical diagnosis of acute (<6 hours) ischemic stroke in the carotid artery territory.
Methods A randomized, double-blind, placebo-controlled multicenter trial was conducted in 232 patients. Because treatment was administered within 6 hours and a CT scan was not mandatory before the start of treatment, 39 patients with either an intracerebral hemorrhage or ischemic stroke in the vertebrobasilar circulation were excluded from the primary efficacy analysis as prespecified in the protocol. Of the 193 patients with acute ischemic stroke in the carotid artery territory (target population), 61 received placebo, 66 lubeluzole 7.5 mg over 1 hour followed by 10 mg/d for 5 days, and 66 lubeluzole 15 mg over 1 hour followed by 20 mg/d for 5 days.
Results The trial, initially aimed at a patient inclusion of 270, was terminated prematurely according to the advice of the Safety Committee because of an imbalance in mortality between the treatment groups. Mortality rates at the final follow-up of 28 days for placebo, lubeluzole 10 mg/d, and lubeluzole 20 mg/d were, respectively, 18%, 6%, and 35% in the target population, results that were confirmed in the intent-to-treat population. Multivariate logistic regression analysis showed that the lower mortality in the lubeluzole 10 mg/d group was significantly in favor of the 10 mg/d treatment (P=.019). The higher mortality rate in the 20 mg/d group could be explained, at least in part, by an imbalance at randomization that led to a higher number of patients in that group with severe ischemic stroke. A total of 26 of 66 patients (39%) who received lubeluzole 10 mg/d had a score on the Barthel Index of >70 at day 28, indicating no or mild disability, compared with 21 of 61 (34%) in the placebo group and 19 of 66 (29%) in the lubeluzole 20 mg/d group (P=NS).
Conclusions In patients with acute ischemic stroke, the dosage regimen of 7.5 mg over 1 hour followed by 10 mg/d of intravenous lubeluzole is safe and statistically significantly reduced mortality. Further clinical trials in a larger number of patients are ongoing to confirm efficacy.
Key Words: cerebral ischemia • neuroprotection • clinical trials • lubeluzole
This article has been cited by other articles:
 |
|
 |
|
  H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bruno, C. Saha, and L. S. Williams Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials Stroke, March 1, 2006; 37(3): 920 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. G. Dyker, A. Sharma, G. A. Ford, M. E. Ardron, and D. G. Grosset Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients : A Dose-Ranging Study Stroke, February 1, 2001; 32(2): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Diener, M. Cortens, G. Ford, J. Grotta, W. Hacke, M. Kaste, P. J. Koudstaal, and T. Wessel Lubeluzole in Acute Ischemic Stroke Treatment : A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo Stroke, November 1, 2000; 31(11): 2543 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick, M. Lu, R. Kothari, S. R. Levine, P. D. Lyden, E. C. Haley, T. G. Brott, J. Grotta, B. C. Tilley, J. R. Marler, et al. Finding the Most Powerful Measures of the Effectiveness of Tissue Plasminogen Activator in the NINDS tPA Stroke Trial Stroke, October 1, 2000; 31(10): 2335 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.E. Arrowsmith, M.J.G. Harrison, S.P. Newman, J. Stygall, N. Timberlake, and W.B. Pugsley Neuroprotection of the Brain During Cardiopulmonary Bypass : A Randomized Trial of Remacemide During Coronary Artery Bypass in 171 Patients Stroke, November 1, 1998; 29(11): 2357 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Management soon after a stroke DTB, July 1, 1998; 36(7): 51 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grotta Lubeluzole Treatment of Acute Ischemic Stroke Stroke, December 1, 1997; 28(12): 2338 - 2346. [Abstract] [Full Text]
|
|
|
|
|
|
M. Haseldonckx, J. Van Reempts, M. Van de Ven, L. Wouters, M. Borgers, and J. A. Clemens Protection With Lubeluzole Against Delayed Ischemic Brain Damage in Rats: A Quantitative Histopathologic Study Stroke, February 1, 1997; 28(2): 428 - 432. [Abstract] [Full Text]
|
|
|
|
|
|
J. Aronowski, R. Strong, J.C. Grotta, and H. A. Kontos Combined Neuroprotection and Reperfusion Therapy for Stroke: Effect of Lubeluzole and Diaspirin Cross-Linked Hemoglobin in Experimental Focal Ischemia Stroke, September 1, 1996; 27(9): 1571 - 1577. [Abstract] [Full Text]
|
|